Zobrazeno 1 - 10
of 197
pro vyhledávání: '"Inge M van Oort"'
Autor:
Cato C. Loeff, Willemijn van Gemert, Bastiaan M. Privé, Inge M. van Oort, Rick Hermsen, Diederik M. Somford, James Nagarajah, Linda Heijmen, Marcel J. R. Janssen
Publikováno v:
EJNMMI Reports, Vol 8, Iss 1, Pp 1-14 (2024)
Abstract Aim The objective of this study was to compare the detection rates of [18F]PSMA-1007 and [18F]Fluciclovine in early biochemical recurrence (BCR) of prostate cancer, i.e. with low prostate-specific antigen (PSA) levels (0.2–5.0 µg/L). Meth
Externí odkaz:
https://doaj.org/article/4e171fc0090c4eb5a269193436755dec
Autor:
Catharina J. P. Op ’t Hoog, Sabien J. E. Bosman, Emmy Boerrigter, Niven Mehra, Inge M. van Oort, Nielka P. van Erp, Wietske Kievit
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: The androgen receptor pathway inhibitors (ARPI), abiraterone acetate and enzalutamide, are commonly used in first-line treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). However, early resistance to ARPI t
Externí odkaz:
https://doaj.org/article/9a2511fa880246ba9f603bf34dde2f7c
Autor:
Niven Mehra, Iris Kloots, Michiel Vlaming, Shafak Aluwini, Els Dewulf, Daniela E. Oprea-Lager, Henk van der Poel, Herman Stoevelaar, Derya Yakar, Chris H. Bangma, Elise Bekers, Roderick van den Bergh, Andries M. Bergman, Franchette van den Berkmortel, Steve Boudewijns, Winand N.M. Dinjens, Jurgen Fütterer, Tom van der Hulle, Guido Jenster, Leonie I. Kroeze, Michel van Kruchten, Geert van Leenders, Pim J. van Leeuwen, Wendy W.J. de Leng, R. Jeroen A. van Moorselaar, Walter Noordzij, Rogier A. Oldenburg, Inge M. van Oort, Irma Oving, Jack A. Schalken, Ivo G. Schoots, Ed Schuuring, Robert J. Smeenk, Ben G.L. Vanneste, Erik Vegt, André N. Vis, Kim de Vries, Peter-Paul M. Willemse, Maurits Wondergem, Margreet Ausems
Publikováno v:
European Urology Open Science, Vol 49, Iss , Pp 23-31 (2023)
Background: Germline and tumour genetic testing in prostate cancer (PCa) is becoming more broadly accepted, but testing indications and clinical consequences for carriers in each disease stage are not yet well defined. Objective: To determine the con
Externí odkaz:
https://doaj.org/article/6f52ae4fdd99475585e6ab93b18449bb
Autor:
Michiel Vlaming, Eveline M. A. Bleiker, Inge M. van Oort, Lambertus A. L. M. Kiemeney, Margreet G. E. M. Ausems
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background In international guidelines, germline genetic testing is recommended for patients with metastatic prostate cancer. Before undergoing germline genetic testing, these patients should receive pre-test counseling. In the standard gene
Externí odkaz:
https://doaj.org/article/ad53d0d396224d62afea041bd2fa2e40
Autor:
Bastiaan M. Privé, Marcel J. R. Janssen, Inge M. van Oort, Constantijn H. J. Muselaers, Marianne A. Jonker, Willemijn A. van Gemert, Michel de Groot, Harm Westdorp, Niven Mehra, J. Fred Verzijlbergen, Tom W. J. Scheenen, Patrik Zámecnik, Jelle O. Barentsz, Martin Gotthardt, Walter Noordzij, Wouter V. Vogel, Andries M. Bergman, Henk G. van der Poel, André N. Vis, Daniela E. Oprea-Lager, Winald R. Gerritsen, J. Alfred Witjes, James Nagarajah
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-4 (2021)
Abstract Background The BULLSEYE trial is a multicenter, open-label, randomized controlled trial to test the hypothesis if 177Lu-PSMA is an effective treatment in oligometastatic hormone-sensitive prostate cancer (oHSPC) to prolong the progression-fr
Externí odkaz:
https://doaj.org/article/d0eae2f7bc184b94b9f6863ede0c30e8
Autor:
Sandra van Wilpe, Donjetë Simnica, Peter Slootbeek, Thomas van Ee, Samhita Pamidimarri Naga, Mark A. J. Gorris, Lieke L. van der Woude, Shabaz Sultan, Rutger H. T. Koornstra, Inge M. van Oort, Winald R. Gerritsen, Leonie I. Kroeze, Michiel Simons, Geert J. L. H. van Leenders, Mascha Binder, I. Jolanda M. de Vries, Niven Mehra
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
Homologous recombination repair deficiency (HRD) is observed in 10% of patients with castrate-resistant prostate cancer (PCa). Preliminary data suggest that HRD-PCa might be more responsive to immune checkpoint inhibitors (ICIs). In this study, we co
Externí odkaz:
https://doaj.org/article/abdf79f8e7f4443f9c8ac5c4111ac941
Autor:
Bastiaan M. Privé, Marcel J. R. Janssen, Inge M. van Oort, Constantijn H. J. Muselaers, Marianne A. Jonker, Michel de Groot, Niven Mehra, J. Fred Verzijlbergen, Tom W. J. Scheenen, Patrik Zámecnik, Jelle O. Barentsz, Martin Gotthardt, Walter Noordzij, Wouter V. Vogel, Andries M. Bergman, Henk G. van der Poel, André N. Vis, Daniela E. Oprea-Lager, Winald R. Gerritsen, J. Alfred Witjes, James Nagarajah
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background In recent years, there is increasing evidence showing a beneficial outcome (e.g. progression free survival; PFS) after metastases-directed therapy (MDT) with external beam radiotherapy (EBRT) or targeted surgery for oligometastati
Externí odkaz:
https://doaj.org/article/05ea3477df904c7e9eba15f0eafa2c79
Autor:
Marie-Christina Jahreiß, Wilma D. Heemsbergen, Bo van Santvoort, Mischa Hoogeman, Maarten Dirkx, Floris J. Pos, Tomas Janssen, Andre Dekker, Ben Vanneste, Andre Minken, Carel Hoekstra, Robert J. Smeenk, Inge M. van Oort, Chris H. Bangma, Luca Incrocci, Katja K. H. Aben
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
PurposeExternal Beam Radiotherapy (EBRT) techniques dramatically changed over the years. This may have affected the risk of radiation-induced second primary cancers (SPC), due to increased irradiated low dose volumes and scatter radiation. We investi
Externí odkaz:
https://doaj.org/article/e94401e37f50411fad083642701633c0
Autor:
Lisanne F. van Dessel, Job van Riet, Minke Smits, Yanyun Zhu, Paul Hamberg, Michiel S. van der Heijden, Andries M. Bergman, Inge M. van Oort, Ronald de Wit, Emile E. Voest, Neeltje Steeghs, Takafumi N. Yamaguchi, Julie Livingstone, Paul C. Boutros, John W. M. Martens, Stefan Sleijfer, Edwin Cuppen, Wilbert Zwart, Harmen J. G. van de Werken, Niven Mehra, Martijn P. Lolkema
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-13 (2019)
Detecting genomic abnormalities in metastatic castration-resistant prostate cancer (mCRPC) may impact clinical treatment. Here, the authors present whole-genome sequencing of metastatic biopsies from 197 mCRPC patients, highlighting the landscape of
Externí odkaz:
https://doaj.org/article/f32d1b1a76f44fc6946c2d126cbc501f
Autor:
Harm Westdorp, Jeroen H. A. Creemers, Inge M. van Oort, Gerty Schreibelt, Mark A. J. Gorris, Niven Mehra, Michiel Simons, Anna L. de Goede, Michelle M. van Rossum, Alexandra J. Croockewit, Carl G. Figdor, J. Alfred Witjes, Erik H. J. G. Aarntzen, Roel D. M. Mus, Mareke Brüning, Katja Petry, Martin Gotthardt, Jelle O. Barentsz, I. Jolanda M. de Vries, Winald R. Gerritsen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-15 (2019)
Abstract Background Clinical benefit of cellular immunotherapy has been shown in patients with castration-resistant prostate cancer (CRPC). We investigated the immunological response and clinical outcome of vaccination with blood-derived CD1c+ myeloi
Externí odkaz:
https://doaj.org/article/4dc02aee961d45088f68d31ad80e605a